Irinotecan + Nimotuzumab
Phase 3Terminated 1 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Gastric Cancer
Conditions
Gastric Cancer, Gastroesophageal Junction Cancer
Trial Timeline
May 13, 2013 → Feb 19, 2018
NCT ID
NCT01813253About Irinotecan + Nimotuzumab
Irinotecan + Nimotuzumab is a phase 3 stage product being developed by Daiichi Sankyo for Gastric Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT01813253. Target conditions include Gastric Cancer, Gastroesophageal Junction Cancer.
What happened to similar drugs?
5 of 20 similar drugs in Gastric Cancer were approved
Approved (5) Terminated (2) Active (14)
Hype Score Breakdown
Clinical
17
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01813253 | Phase 3 | Terminated |
Competing Products
20 competing products in Gastric Cancer